The dermatology market remains highly competitive, with developers ranging from Big Pharma to biotechnology and specialty pharmaceutical firms. In recent years levels of innovation in the area have dwindled, allowing generic competition to erode the market share of several leading brands across major drug classes. As leading players continue to lose ground to smaller, specialised players, opportunities are being created for companies that can implement effective lifecycle management and identify lucrative niches.
‘The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities’
The report assesses the 10 leading companies in the dermatology market, examining their product portfolios and R&D pipelines to provide forecasts of their future competitive positions.
For more information on this report click here
http://www.global-
This report also assesses prevalence rates across the seven major markets in addition to highlighting key trends across the global dermatology area, with coverage of over 95% of the total market.
Discover the key trends and growth drivers of the market for dermatology treatments, assess the competitive dynamics of leading companies and evaluate the future prospects of major products.
This report allows readers to:
• Assess the epidemiology and forecast prevalence of major dermatological disorders including acne, psoriasis, dermatitis, rosacea across key geographies including the UK, Japan, France, Germany, Italy, Spain and the US
• Evaluate the performances and strategies of major dermatology developers by examining the sales focus by drug class, currently marketed products and R&D portfolios of Bayer Schering, Galderma, GSK, Leo Pharma, Novartis, J&J, Roche, Sanofi-Aventis, Schering-Plough and Stiefel Labs
• Examine the market dynamics for the global dermatology area and assess key trends and growth drivers across major treatment classes including corticosteroids, topical anti-infectives, acne and psoriasis
• Forecast revenues for major currently marketed and pipeline dermatology products over 2008-13, with this report’s sales forecasts across major indications, treatment classes and company portfolios
• Identify the strategies that offer the greatest potential for success in the future, measure the impact of recent key events in the dermatology area and understand the latest issues affecting R&D
For more information on this report click here
http://www.global-
Or visit the Global Markets Direct Report Store:
http://www.global-
